Simcere Pharmaceutical Group Limited

SEHK:2096 Stock Report

Market Cap: HK$16.8b

Simcere Pharmaceutical Group Management

Management criteria checks 1/4

Simcere Pharmaceutical Group's CEO is Jinsheng Ren, appointed in Mar 1995, has a tenure of 29.75 years. total yearly compensation is CN¥7.43M, comprised of 67.6% salary and 32.4% bonuses, including company stock and options. directly owns 4.98% of the company’s shares, worth HK$835.58M. The average tenure of the management team and the board of directors is 1.9 years and 5.1 years respectively.

Key information

Jinsheng Ren

Chief executive officer

CN¥7.4m

Total compensation

CEO salary percentage67.6%
CEO tenure29.8yrs
CEO ownership5.0%
Management average tenure1.9yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Nov 21
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable

Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Jul 29
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing

Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

May 01
Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems

Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Dec 29
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market

Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Aug 28
Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates

Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Jun 03
Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?

Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Apr 06
Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically

Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

Jan 10
Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)

With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Aug 16
With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case

Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

Jun 27
Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18

CEO Compensation Analysis

How has Jinsheng Ren's remuneration changed compared to Simcere Pharmaceutical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥1b

Mar 31 2024n/an/a

-CN¥194m

Dec 31 2023CN¥7mCN¥5m

CN¥715m

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥3b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥3mCN¥2m

CN¥931m

Sep 30 2022n/an/a

CN¥972m

Jun 30 2022n/an/a

CN¥1b

Mar 31 2022n/an/a

CN¥1b

Dec 31 2021CN¥2mCN¥2m

CN¥2b

Sep 30 2021n/an/a

CN¥1b

Jun 30 2021n/an/a

CN¥1b

Mar 31 2021n/an/a

CN¥856m

Dec 31 2020CN¥2mCN¥1m

CN¥670m

Sep 30 2020n/an/a

CN¥699m

Jun 30 2020n/an/a

CN¥728m

Mar 31 2020n/an/a

CN¥866m

Dec 31 2019CN¥2mCN¥1m

CN¥1b

Compensation vs Market: Jinsheng's total compensation ($USD1.02M) is above average for companies of similar size in the Hong Kong market ($USD478.20K).

Compensation vs Earnings: Jinsheng's compensation has increased whilst the company is unprofitable.

CEO

Jinsheng Ren (62 yo)

29.8yrs

Tenure

CN¥7,426,000

Compensation

Mr. Jinsheng Ren founded Simcere Pharmaceutical Group Limited in March 1995 and its Chairman since 2023 and serves as its Director and also serves as its Chief Executive Officer since November 19, 2019 an...

Leadership Team

NamePositionTenureCompensationOwnership
Jinsheng Ren
Co-Founder29.8yrsCN¥7.43m4.98%
HK$ 835.6m
Yushan Wan
CFO, Joint Company Secretary & Executive Director2.1yrsCN¥9.36m0.049%
HK$ 8.3m
Renhong Tang
Executive Director1.9yrsCN¥14.53m0.062%
HK$ 10.5m
Xi Wang
VP & Executive Director1.9yrsCN¥1.33mno data
Shen Jun
CFO & Secretary of the Board of Simcere Zaimingless than a yearno datano data
Gaobo Zhou
Chief Investment Officer1.9yrsno datano data
Quanfu Feng
Vice President of Marketingno datano datano data
Tamas Oravecz
Senior VP & Chief Scientific Officer of Simcere Zaiming2.3yrsno datano data
Aik Han Goh
Senior VP & Chief Medical Officerless than a yearno datano data
Wang John
Senior Vice Presidentless than a yearno datano data
Yongyu Wang
Senior VP & Chief Medical Officer of Simcere Zaimingless than a yearno datano data
Wang Feng
Senior VP & Secretary of the Party Committeeless than a yearno datano data

1.9yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 2096's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jinsheng Ren
Co-Founder9.1yrsCN¥7.43m4.98%
HK$ 835.6m
Yushan Wan
CFO, Joint Company Secretary & Executive Director5.1yrsCN¥9.36m0.049%
HK$ 8.3m
Renhong Tang
Executive Director5.1yrsCN¥14.53m0.062%
HK$ 10.5m
Xi Wang
VP & Executive Director1.9yrsCN¥1.33mno data
Jianguo Wang
Independent Non-Executive Director5.1yrsCN¥360.00kno data
Xinhua Wang
Independent Non-Executive Director5.1yrsCN¥360.00kno data
Ruilin Song
Independent Non-Executive Director5.1yrsCN¥360.00kno data
Ka Woon Sung
Independent Non-Executive Director1.9yrsCN¥360.00kno data

5.1yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 2096's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Simcere Pharmaceutical Group Limited is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Shaojing TongBofA Global Research
Bo YuChina International Capital Corporation Limited